Table 1 proportion of clinicopathologic and IHC defined subtypes of BC in Eritrean and Sudanese women
Clinical and tumour characteristics | Origin | Combined both study groups | |||||
|---|---|---|---|---|---|---|---|
Eritrean | Sudanese | ||||||
n | % | n | % | n | % | ||
Histologic type | IDCNST | 89 | 76.7% | 492 | 87.9% | 581 | 85.9% |
ILC | 11 | 9.5% | 18 | 3.2% | 29 | 4.3% | |
others | 16 | 13.8% | 50 | 8.9% | 66 | 9.8% | |
Pathologic tumour size | pT1 | 23 | 19.8% | 82 | 15.5% | 105 | 16.3% |
pT2 | 48 | 41.4% | 248 | 47.0% | 296 | 46.0% | |
pT3 | 37 | 31.9% | 118 | 22.3% | 155 | 24.1% | |
pT4 | 8 | 6.9% | 80 | 15.2% | 88 | 13.7% | |
LN involvement | pN0 | 72 | 62.1% | 198 | 47.3% | 270 | 50.5% |
pN1(1–3) | 15 | 12.9% | 86 | 20.5% | 101 | 18.9% | |
pN2(3–9) | 16 | 13.8% | 78 | 18.6% | 94 | 17.6% | |
pN3(>9) | 13 | 11.2% | 57 | 13.6% | 70 | 13.1% | |
Grading | GI | 10 | 8.6% | 20 | 3.6% | 30 | 4.4% |
GII | 46 | 39.7% | 306 | 54.6% | 352 | 52.1% | |
GIII | 60 | 51.7% | 234 | 41.8% | 294 | 43.5% | |
LVI | NO | 44 | 37.9% | 264 | 46.9% | 308 | 45.2% |
unknown | 6 | 5.1% | 111 | 19.8% | 117 | 17.3% | |
YES | 56 | 48.3% | 185 | 15.2% | 102 | 35.5% | |
ER | ER negative. | 59 | 50.9% | 308 | 55.0% | 367 | 54.3% |
ER positive. | 57 | 49.1% | 252 | 45.0% | 309 | 45.7% | |
PR | PR negative | 69 | 59.5% | 346 | 61.8% | 415 | 61.4% |
PR positive | 47 | 40.5% | 214 | 38.2% | 261 | 38.6% | |
HR | HR positive | 57 | 49.1% | 257 | 45.9% | 314 | 46.4% |
HR negative | 59 | 50.9% | 303 | 54.1% | 362 | 53.6% | |
HER2 | negative | 82 | 70.7% | 296 | 71.3% | 378 | 71.2% |
positive | 34 | 29.3% | 119 | 28.7% | 153 | 28.8% | |
|  | Missing | 0 | 0 | 147 | – | 147 | – |
IHC based breast cancer subtype | Luminal A-like | 43 | 37.1% | 153 | 36.9% | 196 | 36.9% |
Luminal B-like | 14 | 12.1% | 54 | 13.0% | 68 | 12.8% | |
HER2 enriched | 20 | 17.2% | 65 | 15.7% | 85 | 16.0% | |
TNBC | 39 | 33.6% | 143 | 34.5% | 182 | 34.3% | |